Inflammatory bowel diseases (including IBD, exempli fied by Crohn's disease and ulcerative colitis) are chronic relapsing disorders affecting the gastrointestinal tract. IBD has a progressive and destructive nature and, there fore, can cause various complications including steno ses, abscesses, fistulas, extraintestinal manifestations and colitisassociated neoplasias and cancer 1,2 . Thus, effective therapeutic approaches are of high clinical rele vance in patients with IBD. This Review summarizes current therapeutic strategies and highlights emerging new treatment approaches for IBD with special refer ence to the proposed molecular mechanisms of action of antiinflammatory drugs.
Current IBD therapies Classic anti-inflammatory drugs. 5Aminosalicylates (5ASAs) are important antiinflammatory drugs that are frequently used for antiinflammatory therapy in patients with ulcerative colitis 3 . By contrast, 5ASA based drugs show little or no efficacy in inducing res olution of clinical symptoms and tissue inflammation in patients with Crohn's disease 4 . 5ASAs are effective for induction and mainten ance of remission in ulcerative colitis and might also reduce the risk of developing colitisassociated tumours in these patients 5 . Several mechanisms of action for 5ASAs have been proposed, including reduction of prostaglandin synthesis via inhibition of cyclooxygenase, suppression of proinflammatory cytokine production and oxygenfree radicals, inhib ition of lipoxygenase, blockade of neutrophil chemo taxis and mast cell activation, and impairment of nuclear factorκB activation (NFκB) in immune cells 3 . Moreover, studies in mice revealed that 5ASAbased drugs augment peroxisome proliferatoractivated receptorγ (PPARγ) expression and promote PPARγ translocation from the cytoplasm to the nucleus where they result in activation of peroxisomeproliferator hormone response elementdriven genes to suppress colitis activity 6, 7 . In addition to 5ASAs, corticosteroids (systemically or topically delivered) have been used for remission induction in ulcerative colitis 2 . Although cortico steroids favour induction of remission in both ulcer ative colitis and Crohn's disease, they are not suitable for mainten ance of remission in IBD 1, 2 . Mechanistically, gluco corticoids bind to a specific cytosolic receptor fol lowed by translocation of the complex to the nucleus to either activate or repress gene transcription (via bind ing to DNA corticosteroidresponse elements) 8, 9 . Additionally, the glucocorticoid-receptor complex can inactivate pro inflammatory transcription factors such as NFκB and activator protein 1 (AP1) via proteinprotein inter actions, thereby preventing their activation of inflammatory mediators (for example, leukotrienes and cytokines such as IL1 and IL6).
Classic immunosuppressive drugs.
Classic immunosup pressive drugs for IBD therapy include azathioprine or 6mercaptopurine [10] [11] [12] [13] [14] , methotrexate 15 and ciclosporinA or tacrolimus 16 . The latter drugs have been used in stud ies for induction of remission in patients with ulcer ative colitis, methotrexate has been used for induction and maintenance of remission in Crohn's disease and azathio prine is frequently used for mainten ance of remission in both Crohn's disease and ulcerative coli tis 14, 15, 17 . Several in vitro and in vivo studies have high lighted the potential mechanism of action of these drugs. CiclosporinA and tacrolimus bind to speci fic intra cellular receptors (immunophilins) and act by blocking the activation of the transcription factor nuclear fac tor of activated T cells (NFAT) that controls cytokine gene transcription and apoptosis resistance of lympho cytes 18, 19 . Moreover, methotrexate affects survival of immune cells by blocking cell proliferation and indu cing apoptosis 20 . This drug also increases endogenous adeno sine release, alters expression of cellular adhesion mol ecules and suppresses production of proinflammatory cytokines 21 . Finally, azathioprine and 6mercaptopurine are metabolized to 6thioguanine triphosphates that bind to the small GTPase RAC1, thereby suppress ing the guanine exchange activity of VAV1 on RAC1 (REFS 10, 11, 22) . Thus, RAC1 activation is suppressed, leading to inhibited activation of cells in both the innate and adaptive immune systems. In T cells for instance, azathioprine and 6mercaptopurine can cause apoptosis through RAC1 inhibition 10 . Furthermore, Tcell apopto sis has been shown to correlate with responsiveness to azathioprine or 6mercaptopurine in patients with IBD 10 .
Biologic therapy with anti-TNF agents. As many patients with IBD were either refractory or intolerant to treat ment with the classic agents already discussed, there was an urgent need for the development of more specific novel therapeutic approaches. In this context, antiTNF agents, including infliximab, adalimumab, golimumab and certo lizumab pegol, were introduced into clin ical therapy for IBD 14, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . For instance, infliximab was shown to be effective for induction and maintenance of remission in both Crohn's disease and ulcerative colitis as well as for treatment of fistulas in Crohn's disease, highlighting the broad relevance of antiTNF therapy 14, 24 . In 2015 and 2016, infliximab biosimilars -biological products that are highly similar in structure and clinical efficacy to an already FDAapproved biological reference product -were approved for clinical therapy and adalimumab biosimilars are currently under development 34 . AntiTNF agents such as infliximab can be combined with immunosuppressive agents such as azathioprine in IBD. In fact, prospective clinical trials 14, 35 showed that combination therapy with infliximab and azathioprine is superior to induce corticosteroidfree clinical remis sion than monotherapy with either agent in both Crohn's disease and ulcerative colitis. Further studies indi cated that initiation of more intensive treatment early in the course of the disease could result in improved outcomes 36, 37 . Specifically, early combined immuno suppression (socalled topdown therapy with early azathioprine plus infliximab followed by de escalation if possible) reduced the risk of major adverse outcomes in Crohn's disease as compared with conventional manage ment (socalled stepup therapy: first cortico steroids, followed, in sequence, by azathioprine and then infliximab). Although early combined immuno suppression was not associated with an increased risk of serious drugrelated adverse events or mortality in sev eral studies 34, 37 , future studies will have to determine the risk of adverse events of longterm combined immuno suppressive therapy. The described combination therapy with immunosuppressive agents and TNF antagonists is probably the best strategy for achieving optimal out comes in patients at high risk of disease progression (for example, fistulizing or extensive disease). However, longterm prospective studies are still needed to under stand the value of early combination therapy to prevent bowel damage, loss of gastrointestinal tract function and permanent disability 38 . TNF is produced by various immune and non immune cells in the inflamed gut of patients with IBD, including macrophages, T cells, dendritic cells, fibroblasts and fat cells 39 . This cytokine has pleiotropic effects in the bowel wall: it induces neoangiogenesis 40 ; activates macrophages to produce proinflammatory cytokines; favours Paneth cell death via necroptosis 41 ; augments apoptosis of intestinal epithelial cells 42 ; regu lates Tcell apoptosis 40, 43, 44 ; and reduces production of tissue inhib itor of matrix metalloproteinases (MMPs) by fibroblasts to mediate tissue injury via activated MMPs 45 . Thus, antiTNF antibodies can suppress intestinal inflammation in IBD through several mechanisms.
However, the antiTNF agent etanercept has shown no efficacy in patients with Crohn's disease 46 , suggest ing differences among antiTNF drugs. Several potential explanations for this observation have been suggested. First, differences in tissue degradation of antiTNF antibodies were found. After MMP3 and MMP12 induced proteolytic degradation, cleaved infliximab and adalimumab functioned as F(ab')2 fragments, whereas cleaved etanercept lost its ability to neutralize TNF 47 . This finding suggests that rapid MMPinduced 49 . Membranebound TNF, however, is an important costimulatory signal for TNFR2 on mucosal T cells in IBD and mediates their resistance to apoptosis 43 . Thus, other TNF block ers might more effectively induce Tcell apoptosis than etanercept and such apoptosis induction has been shown to correlate with clinical responses to antiTNF therapy in vivo 44 . Consistently, the presence of membrane bound TNF on mucosal immune cells in vivo has been identi fied as a predictor of response to subsequent anti TNF therapy 50 , further highlighting the relevance of membranebound TNF in IBD pathogenesis.
Current and emerging drugs T-cell trafficking: integrin blockers and beyond. Studies over the past 10 years have found that ~30-50% of patients with IBD do not respond to antiTNF therapy, indicative of the need for new therapies. Experimental studies indicated that blockade of activated lympho cyte homing to the inflamed gut might provide a new approach for therapy of intestinal inflammation 51, 52 . Subsequently, the antiα4 integrin antibody natalizumab was tested in clinical trials for Crohn's disease therapy to block Tcell homing to the inflamed intestine via α4β7 integrins [53] [54] [55] (FIG. 1) . However, in spite of evidence for clinical efficacy in Crohn's disease, treatmentrelated JC virus infections causing progressive multifocal leuko encephalopathy limited the use of this agent in IBD therapy 56 . For example, in JC virusseropositive patients with prior immunosuppressant use, the incidence of progressive multifocal leukoencephalopathy during months 25-48 of natalizumab therapy was reported to be 19.5 per thousand; without prior immuno suppressant use, the incidence during months 25-48 was ~7.4 per thousand 57 . These infections were prob ably related to natalizumabinduced blockade of Tcell homing to the brain via α4β1 integrins, suggesting that a more specific blockade of α4β7 integrins was important. Subsequently, the α4β7integrinspecific antibody vedolizumab was developed and showed efficacy in clinical phase III trials for remission induction and maintenance in Crohn's disease and ulcerative colitis [58] [59] [60] [61] [62] [63] . Although controlled clinical trials suggested that vedolizumab might induce more rapid clinical remis sion in ulcerative colitis than in Crohn's disease 59, 60 , sub sequent realworld data confirmed efficacy of this drug for moderate-severe Crohn's disease in routine clinical practice 64 with similar rates of longterm remission in Crohn's disease and ulcerative colitis 65 . The reasons for potential differences between vedolizumab in Crohn's disease versus ulcerative colitis remain to be deter mined. Clinically, vedolizumab and TNF blockers are usually considered as alternative firstline induction treatment for patients with moderate-severe Crohn's disease and ulcerative colitis despite conventional ther apy (with cortico steroids). Additionally, vedolizumab can be used in patients already exposed to antiTNF agents. Prospective studies comparing vedolizumab with TNF blockers such as infliximab in antiTNF agent naive patients will determine the precise position ing of vedolizu mab in the treatment algorithm for IBD. On the basis of the success of the antiα4β7 integrin approach with vedolizumab, further therapies target ing Tcell homing are currently tested in clinical trials including antiMAdCAM1 antibodies (PF00547659) and the antiβ7 integrin antibody etrolizumab [66] [67] [68] (FIG. 1) .
The latter drug is particularly interesting, as it blocks not only α4β7mediated homing but additionally Tcell retention via inhibition of αE(CD103)β7mediated bind ing to Ecadherin on gut epithelial cells 66, 67 . Consistently, in a humanized mouse model of colitis with ulcerative colitis T cells, etrolizumab was superior to vedolizumab in reducing Tcell trafficking in the inflamed tissue due to effects on ulcerative colitis Tcell retention 66 . However, phase III clinical data on clinical efficacy and safety of etrolizumab are still missing, although phase II data indicated efficacy for induction of remission in ulcerative colitis 67 . Another important development in the context of immune cell trafficking in IBD relates to sphingosine 1phosphate (S1P) signalling 69 . The bioactive lipid S1P has been shown to activate NFκB and STAT3 tran scription factors via a family of five G proteincoupled receptors (S1PR) expressed on lymphocytes (socalled insideout signalling). Functionally, S1PR signalling induces cell proliferation, vascular permeability and angiogenesis 69 . Moreover, S1PR expressed in immune cells controls their egress from lymph nodes to lymph and plasma and S1PR agonists cause lymphopenia in blood and thoracic duct lymph by cell sequestration in lymph nodes 69 . Inhibition of lymphocyte recirculation via S1PR signalling suppressed experimental colitis and development of colitisassociated neoplasias in mice [70] [71] [72] . Thus, S1P receptor agonists (ozanimod (formerly known as RPC1063), APD334 and MT1303) have been tested in human ulcerative colitis. For instance, ozanimod is an oral agonist of S1PR subtypes 1 and 5 that induces peripheral lymphocyte sequestration. A phase II trial indicated that ozanimod (daily dose of 1 mg) results in a slightly higher clinical remission rate in ulcerative colitis than placebo, suggesting that such drugs might be therapeutically effective in human ulcerative coli tis 73 . However, further prospective studies are needed to determine efficacy and safety of ozanimod treatment in ulcerative colitis.
Emerging targets in fibrosis and tissue remodelling.
Tissue remodelling and destruction in patients with IBD is controlled by MMPs. In this context, expression of MMP9 was found to be increased in IBD, particularly in patients with ulcerative colitis 74 . Functional data in experimental models of inflammation have suggested an important role of MMP9 in impairing colonic epi thelial permeability and augmenting inflammation via activation of myosin light chain kinase (MLCK) 74 . Furthermore, MMP9 favoured angiogenesis and created a proteolytic environment in the inflamed gut of a mouse model of colitis that stimulated the influx of myeloid cells into the colonic epithelium and the prod uction of TNF 75, 76 . Consecutively, a potent and highly selective allosteric MMP9 inhibitor (humanized mono clonal antibody GS5745) has been developed and is currently being tested in clinical trials in patients with IBD 76 (FIG. 2) . However, in September 2016, the com pany has stopped its combined phase II/III clin ical study of GS5745 among patients with moderately to severely active ulcerative colitis due to insufficient evi dence of a treatment benefit in the group of patients randomly assigned to receive either one of two doses of GS5745 (REF. 77 ).
To ameliorate tissue fibrosis in IBD, enzymes con trolling degradation of matrix compounds might be druggable targets. Specifically, a study has examined carbohydrate sulfotransferase 15 (CHST15) in gut inflammation 78 . CHST15 is a specific enzyme bio synthesizing chondroitin sulfate E that binds to vari ous pathogenic mediators and favours tissue fibrosis. In experimental acute dextran sulfate sodium colitis, smallinterfering RNA (siRNA)based silencing of CHST15 reduced colitis activity and intestinal accumu lation of F4/80 + macrophages and ERTR7 + fibroblasts. In chronic dextran sulfate sodium colitis, CHST15 Nature Reviews | Gastroenterology & Hepatology siRNA reduced colitis activity and numbers of αSMA (smooth muscle actin)positive fibroblasts and collagen deposition. Furthermore, a phase I study in 18 patients with Crohn's disease published in 2016 determined the safety of STNM01, a synthetic doublestranded RNA oligonucleotide directed against CHST15, in Crohn's disease 79 . The majority of individuals who received STNM01 showed a reduction of endoscopic inflam mation as compared with placebo therapy. Moreover, histo logical analyses revealed that STNM01 reduces tissue fibrosis in Crohn's disease. Larger prospective studies on this compound are needed to determine the efficacy of this new therapeutic approach.
T cell
New blockers of proinflammatory cytokines and cytokine signalling. On the basis of the success of anti TNF agents in IBD there has been an intensive search for additional effective anticytokine strategies. However, several studies on new cytokine blockers have yielded disappointing results. For instance, the antiIFNγ anti body fontolizumab showed low efficacy in patients for treatment of active Crohn's disease 80 . Moreover, the antiIL17A antibody secukinumab resulted in aggrav ation of Crohn's disease in many patients, possibly owing to the protective effects of IL17A on gut epi thelial cells [81] [82] [83] . Consistently, IL17A inactivation did not result in amelioration of experimental colitis in mice 84, 85 . In addition to IFNγ and IL17A blockers, two prospective studies did not show efficacy of antiIL13 antibodies (anrukinzumab, tralokinumab) in patients with ulcerative colitis despite promising results in animal models of colitis [86] [87] [88] [89] . In contrast to these observations, additional cytokine blockers have shown more promis ing results in clinical trials that will be reviewed in the next paragraphs (FIGS 3,4) .
IL6 is a proinflammatory cytokine activating immune cells 90, 91 . In patients with IBD, levels of IL6 and its agonistic soluble receptor (sIL6R) are induced and mediate activation of T cells and their resistance against programmed cell death (apoptosis) 92 . In experi mental colitis models, IL6R blockade was effective in suppressing intestinal inflammation. Consistently, a small pilot study using an antiIL6R antibody (tocili zumab, previously known as MRA) suggested higher response and remission rates in Crohn's disease than the placebo group 93 . Additionally, according to results pre sented in abstract form, an IL6 antibody (PF04236921) yielded higher clinical response (Crohn's disease activity index70) and remission rates in patients with Crohn's disease than placebo therapy 94 . However, cases with abscess formation and perforations were noted upon start of therapy possibly owing to protective, proliferative effects of membranebound IL6R signalling on gut epi thelial cells. In future studies, gp130-Fc fusion proteins could elucidate the role of sIL6R signalling in Crohn's disease, as such proteins specifically block signalling via the soluble but not the membranebound IL6R.
IL12 p35-p40 and IL23 p19-p40 are two hetero dimeric, proinflammatory cytokines that are induced in the inflamed mucosa of patients with Crohn's dis ease 95, 96 . Consistent with the type 1 T helper (T H 1) inducing potential of IL12, Crohn's disease was found to be associated with mucosal T H 1 responses. Moreover, type 17 T helper (T H 17) responses were noted in both patients with Crohn's disease and ulcerative colitis 39, 97 , possibly owing to the presence of IL23 as a wellknown activator of T H 17 T cells. These data provided a rational basis for targeting of T H 1 and T H 17 cytokines in IBD (FIG. 2) . Functional studies with genetically engineered animals and IL23 p19 and p40 blockers suggested that blockade of these cytokine subunits might effectively suppress intestinal inflammation in mouse models of colitis [98] [99] [100] [101] [102] [103] [104] . In particular, IL23 inhibition was effective and prevented activation of T cells and innate lymphoid cells and tissue destruction in vivo.
Subsequently, various antibodies against IL12-IL23 p40 and IL23 p19 subunits were developed for clinical trials (such as ABT874, ustekinumab, risanki zumab, LY2525623, AMG139/MEDI2079 and guselku mab) [105] [106] [107] . Studies with ABT874 and ustekinumab as p40 blockers demonstrated higher response rates in patients with Crohn's disease than placebo. Initial studies also revealed that ustekinumab was particularly effective for therapy in patients with Crohn's disease who had previously taken antiTNF agents 105, 106 . On the basis of successful phase III studies in both antiTNF agent naive and antiTNF agentexperienced patients (UNITI1 and UNITI2 programmes), ustekinumab was recently approved for Crohn's disease therapy in the USA and in Europe) 108 . Potentially, p19 blockers such as risankizu mab will also be available for Crohn's disease therapy in the future, as the latest phase II data presented as a late breaker abstract suggested efficacy for this antibody in patients with active Crohn's disease 109 . Cytokine signalling is mediated upon binding of cytokines to their specific receptors via intracellular activation of Janus kinases (JAKs: JAK1, JAK2, JAK3, TYK2). Thus, blockade of JAK kinases might be used to suppress cytokine signalling in mucosal immune cells. As individual JAKs mediate cell activation via sev eral cytokines (for example, JAK3 is activated via IL2, IL4, IL7, IL9, IL15 and IL21) with proposed pro inflammatory roles in colitis [110] [111] [112] [113] , this approach opens the possibility to block the activity of several pro inflammatory cytokines simultaneously. Indeed, several JAK inhibitors (tofacitinib, ABT494 and filgo tinib) have been developed for clinical therapy 114, 115 . Interestingly, the JAK1-JAK3 blocker tofacitinib, a sup pressor of Tcell, naturalkillercell and Bcell activ ation, yielded very promising results in a phase II study in patients with ulcerative colitis, but was not effective in patients with Crohn's disease 114, 115 . Moreover, filgotinib, a selective JAK1 inhibitor, showed increased remission rates in patients with moderate to severe Crohn's dis ease 116 . Although the efficacy and safety profiles of these drugs will have to be determined in large phase III trials, these findings indicate that JAK inhibitors hold promise for clinical therapy of patients with IBD. Finally, phosphodiesterase (PDE)4 inhibitors are currently being tested in patients with IBD. PDE4 inhibitors such as apremilast and roflumilast regulate inflammatory processes by degrading cyclic adenosine 3'5' monophosphate (cAMP), a key second messen ger 117 . Inhibition of PDE4 increases the intracellular cAMP level, which in turn blocks proinflammatory mediators and favours production of anti inflammatory proteins. In particular, apremilast has been found to impair the production of the proinflammatory cytokines IFNγ, TNF, IL12, IL17 and IL23 (REF. 118 ), indicating that PDE4 blockers are multicytokine inhibitors with potential therapeutic effects in IBD. 121, 122 , these data suggested that targeting of ROR proteins might be useful in these patients. Moreover, both genetic and pharmacological (via DNAzyme) blockade of GATA3, a key transcription factor for T H 2 cytokine gene tran scription, ameliorated chronic oxazolonemediated and TNBS (2,4,6trinitrobenzenesulfonic acid)mediated colitis in mice 119 . As GATA3 expression is induced in patients with active ulcerative colitis and correlates with T H 2 and T H 9 cytokine levels in this disease, these observations indicate that GATA3 might be targeted for therapy of ulcerative colitis in humans. Indeed, GATA3 DNAzyme therapy has been successfully tested in patients with asthma 123 , a chronic inflammatory dis order of the airways associated with type 2 T helper (T H 2) cytokine production.
Blockers of transcription factors
Strengthening barrier function and activation of anti-inflammatory pathways. Escherichia coli Nissle (EcN) is a nonpathogenic Gramnegative strain that controls intestinal barrier function and induces anti inflammatory proteins 124, 125 . EcN is an established clinical therapy for patients with ulcerative colitis and exhibits similar antiinflammatory effects com pared with 5ASAs 125 . EcN has direct antimicrobial effects, controls biofilm formation, stimulates human βdefensin production by intestinal epithelial cells, and strengthens tight junctions by upregulating zonula occludens proteins 125 . In addition to this probiotic strain, several other probiotic approaches as well as faecal transplantation have been considered for IBD therapy, although unequivocal results have been obtained 126, 127 . However, a randomized controlled trial in adults with active ulcerative colitis demonstrated that faecal micro biota transplantation (50 ml, via enema from healthy anonymous donors) once weekly for 6 weeks induced markedly higher remission rates than placebo 126 . Further studies are required to determine the efficacy and safety of this approach in larger patient cohorts and over longer time periods.
Additional therapeutic approaches for IBD have been designed that might regulate barrier function and antiinflammatory pathways. Defects in mucin produc tion are wellknown in patients with ulcerative colitis 128 , and so phosphatidylcholine (lecithin) therapy has been tested in patients with promising results in phase II studies 129 . The results of the phase III study in patients with ulcerative colitis are expected in 2017. Moreover, IL22 therapy or modulation of IL22binding protein have been tested successfully in mouse colitis models and proposed as new approaches for IBD therapy 130 . The IL22 cytokine directly activates proliferation of intes tinal epithelial cells via STAT3 activation and induces production of protective barrier proteins such as REG proteins 131 . Moreover, modulators of Tolllike receptor (TLR) signalling have been considered for IBD ther apy 132 . CpGsitecontaining oligonucleotides suppress immune cell activation and protect barrier function in experimental colitis via TLR9 signalling 133 . Finally, the TLR7 ligand imiquimod suppressed CD11c + den dritic cells and activated intestinal epithelial cells to produce antimicrobial peptides, resulting in reduced colitis activity 134 .
The ratio between effector T cells and regulatory T (T reg ) cells is markedly increased in patients with IBD 135 . Thus, it is tempting to speculate that increasing T reg cell numbers via T reg cell transfer might restore the bal ance between proinflammatory and anti inflammatory immune cells as a new therapeutic approach in IBD. Indeed, naturally occurring T reg cells, TGFβinduced T reg cells as well as ex vivo expanded T reg cells have been used for therapy of experimental colitis in mice and led to suppressed colitis activity induced by effector T cells 136, 137 . In patients with IBD, a 12week, single injection, escalating dose, phase I/IIa clinical pilot study in refractory Crohn's disease with ovalbumin specific T reg cells was well tolerated and had doserelated efficacy 138 (FIG. 3) . On the basis of these results, various clinical studies are currently studying the effects of T reg cell based immune therapy in IBD.
Finally, activation of TGFβ signalling in immune cells via inhibition of SMAD7 has been tested in a phase II study in patients with Crohn's disease 139, 140 . This study was based on previous findings showing that blockade of SMAD7 expression in experimental colitis augmented TGFβ signalling via SMAD3 and caused suppression of colitis activity. The clinical phase II trial with an anti sense SMAD7 blocker, denoted mongersen, showed markedly higher rates of remission and clinical response in mongersentreated patients than the placebotreated group. Owing to these promising results of the phase II programme, a phase III study will determine the efficacy and safety of mongersen in a larger group of patients with Crohn's disease.
Stem cells for Crohn's disease fistulas. Crohn's disease is associated with the development of complex fistulas that are challenging to treat 141, 142 . Adiposederived allo geneic stem cells have been considered as new treatment approaches for such fistulas 142, 143 . Experimental studies revealed that mesenchymal stem cells (MSCs) might exert potent immunomodulatory effects on antigen specific T cells in Crohn's disease through paracrine and cell-cell contactmediated actions 144 . Clinically, local administration of allogeneic, expanded MSCs in initial trials was not associated with severe adverse events in patients with Crohn's disease who had perianal fistulas and seemed to promote healing. A large random ized trial subsequently showed that allogeneic MSCs (120 million Cx601 cells) induced remission (closure of external openings of fistulas and absence of collections >2 cm) more frequently than placebo 145 . Furthermore, a phase I-IIa study suggested potential beneficial effects of MSCs in rectovaginal fistulas in Crohn's disease, suggest ing that MSCs might be broadly applicable for fistula therapy in patients with Crohn's disease 146 .
Conclusions
Several new drugs such as antiTNF agents and vedoli zumab have been introduced into clinical IBD therapy in the past few decades that have helped to reduce cortico steroid use and to augment response and remission rates. Evidence in both Crohn's disease and ulcer ative colitis has been obtained that indicate some of these drugs synergistically suppress immune cell activation and gut inflammation (for example, azathioprine plus infliximab), highlighting the potential of combination therapies 14, 35 . However, there is still a large unmet need for novel therapeutic approaches as many patients do not respond to the clinically approved drugs, including TNF blockers and vedolizumab 14, 28, 60 . Thus, a plethora of new drugs are currently being tested in clinical trials in IBD that challenge established treatment regimens (FIG. 2) . Many of these new therapeutic approaches have been developed on the basis of studies in IBD mouse models, genetic studies, analyses of IBD tissues and new insights into inflammatory pathways in other chronic inflammatory disorders, such as rheumatoid arthritis and psoriasis 97, 117, 147, 148 . Some of these new agents might gain approval by FDA and the European Medicines Agency and might enable new strict end points in IBD therapy to be achieved 149, 150 , including mucosal healing on endoscopy, deep remission (clin ical remission plus mucosal healing), transmural healing and histological healing, thereby raising the bar for future drugs in IBD therapy and possibly preventing severe IBDassociated complications such as surgery and hospitalizations. In this context, new cytokine and signalling block ers have yielded promising results and will probably add to our future clinical armamen tarium in patients with IBD 106, 115 . With the introduction of additional approved drugs in the future, it will be of crucial impor tance to identify biomarkers to predict and monitor therapeutical success to enable individualized therapy in IBD.
